Viking Therapeutics, Inc.
VKTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001607678
In the last 90 days, Viking Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 437 institutions reported holding it in 13F filings for Q2 2026, worth $2.96B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Viking Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $6.27M in total
- Insiders trading
- 3
- Net value
- −$6.27M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Viking Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kelly-Gemmell Dorothy Elizabeth | Director | 6,333 | Aug 7, 2026 | 1 |
| Lian Brian | President & CEO | 2,572,441 | Jul 29, 2026 | 3 |
| Zante Greg | Chief Financial Officer | 212,204 | Jul 29, 2026 | 3 |
| Mancini Marianna | Chief Operating Officer | 422,760 | Jul 29, 2026 | 3 |
| Chen Hubert C | Chief Medical Officer | – | Jun 3, 2026 | 1 |
| Aubuchon Neil William | Chief Commercial Officer | 4,475 | Mar 10, 2026 | 2 |
| Foehr Matthew W | Director | 135,186 | Jan 5, 2026 | 1 |
| Singleton J Matthew | Director | 12,650 | Jan 5, 2026 | 1 |
| Rowland Charles A Jr | Director | 33,150 | Jan 5, 2026 | 2 |
| Macartney Lawson | Director | 51,115 | Jan 5, 2026 | 1 |
| Rouan Sarah Kathryn | Director | 4,390 | Jan 5, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 18, 2023 (view filing) | Apr 17 | 1 day | Zante GregChief Financial Officer | SSaleCommon Stock, par value $0.00001 per share | −7.50K | $20.00 | −$150.0K | −4.8%149.3K after | |
| Apr 13, 2023 (view filing) | Apr 13 | Same day | Lian BrianPresident & CEO | SSaleCommon Stock, par value $0.00001 per share | −79.3K | $18.45 | −$1.46M | −3.3%2.31M after | |
| Apr 13, 2023 (view filing) | Apr 11-12 | 2 days | Zante GregChief Financial Officer | SSaleCommon Stock, par value $0.00001 per share | −97.8K | $18.00 | −$1.76M | −39.6%149.3K after | 2 lots |
| Apr 3, 2023 (view filing) | Mar 30-Apr 3 | 4 days | Lian BrianPresident & CEO | SSaleCommon Stock, par value $0.00001 per share | −243.4K | $17.31 | −$4.21M | −9.8%2.23M after | 4 lots |
| Apr 3, 2023 (view filing) | Mar 30-Apr 3 | 4 days | Zante GregChief Financial Officer | SSaleCommon Stock, par value $0.00001 per share | −161.9K | $17.19 | −$2.78M | −52.3%147.8K after | 2 lots |
| Mar 30, 2023 (view filing) | Mar 28-29 | 2 days | Mancini MariannaChief Operating Officer | SSaleCommon Stock, par value $0.00001 per share | −237.8K | $15.17 | −$3.61M | −47.6%261.9K after | 2 lots |
| May 3, 2022 (view filing) | May 2 | 1 day | Foehr Matthew WDirector | PPurchaseCommon Stock, par value $0.00001 per share | +45.0K | $2.47 | +$111.2K | +67.9%111.3K after |